How to buy Bio-Techne Corporation stock

Bio-Techne Corporation is a biotechnology business based in the US. Bio-Techne Corporation shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Techne Corporation employs 2,300 staff and has a trailing 12-month revenue of around 0.00.

Bio-Techne Corporation share price

Use our graph to track the performance of TECH stocks over time.

Bio-Techne Corporation shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$202.46 - $434.69
50-day moving average	$389.30
200-day moving average	$336.54
Wall St. target price	$422.78
PE ratio	98.7776
Dividend yield	$1.28 (0.3%)
Earnings per share (TTM)	$4.40

Buy Bio-Techne Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Bio-Techne Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Bio-Techne Corporation by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Bio-Techne Corporation under- or over-valued?

Valuing Bio-Techne Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bio-Techne Corporation's P/E ratio

Bio-Techne Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 99x. In other words, Bio-Techne Corporation shares trade at around 99x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Bio-Techne Corporation's PEG ratio

Bio-Techne Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.4316. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bio-Techne Corporation's EBITDA

Bio-Techne Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $234.3 million.

The EBITDA is a measure of a Bio-Techne Corporation's overall financial performance and is widely used to measure a its profitability.

Bio-Techne Corporation financials

Revenue TTM	$799 million
Operating margin TTM	23.12%
Gross profit TTM	$483.2 million
Return on assets TTM	5.68%
Return on equity TTM	12.25%
Profit margin	21.9%
Book value	$39.26
Market capitalisation	$16.9 billion

TTM: trailing 12 months

Shorting Bio-Techne Corporation shares

There are currently 384,303 Bio-Techne Corporation shares held short by investors – that's known as Bio-Techne Corporation's "short interest". This figure is 5.4% down from 406,378 last month.

There are a few different ways that this level of interest in shorting Bio-Techne Corporation shares can be evaluated.

Bio-Techne Corporation's "short interest ratio" (SIR)

Bio-Techne Corporation's "short interest ratio" (SIR) is the quantity of Bio-Techne Corporation shares currently shorted divided by the average quantity of Bio-Techne Corporation shares traded daily (recently around 213501.66666667). Bio-Techne Corporation's SIR currently stands at 1.8. In other words for every 100,000 Bio-Techne Corporation shares traded daily on the market, roughly 1800 shares are currently held short.

However Bio-Techne Corporation's short interest can also be evaluated against the total number of Bio-Techne Corporation shares, or, against the total number of tradable Bio-Techne Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Techne Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bio-Techne Corporation shares in existence, roughly 10 shares are currently held short) or 0.0111% of the tradable shares (for every 100,000 tradable Bio-Techne Corporation shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Techne Corporation.

Find out more about how you can short Bio-Techne Corporation stock.

Bio-Techne Corporation share dividends

Dividend payout ratio: 23.53% of net profits

Recently Bio-Techne Corporation has paid out, on average, around 23.53% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.3% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne Corporation shareholders could enjoy a 0.3% return on their shares, in the form of dividend payments. In Bio-Techne Corporation's case, that would currently equate to about $1.28 per share.

While Bio-Techne Corporation's payout ratio might seem low, this can signify that Bio-Techne Corporation is investing more in its future growth.

Bio-Techne Corporation's most recent dividend payout was on 25 February 2021. The latest dividend was paid out to all shareholders who bought their shares by 10 February 2021 (the "ex-dividend date").

Have Bio-Techne Corporation's shares ever split?

Bio-Techne Corporation's shares were split on a 2:1 basis on 3 December 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Techne Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Techne Corporation shares which in turn could have impacted Bio-Techne Corporation's share price.

Bio-Techne Corporation share price volatility

Over the last 12 months, Bio-Techne Corporation's shares have ranged in value from as little as $202.464 up to $434.69. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne Corporation's is 1.1042. This would suggest that Bio-Techne Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Bio-Techne Corporation overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.

Frequently asked questions

• What percentage of Bio-Techne Corporation is owned by insiders or institutions?

  Currently 0.564% of Bio-Techne Corporation shares are held by insiders and 93.967% by institutions.

• How many people work for Bio-Techne Corporation?

  Latest data suggests 2,300 work at Bio-Techne Corporation.

• When does the fiscal year end for Bio-Techne Corporation?

  Bio-Techne Corporation's fiscal year ends in June.

• Where is Bio-Techne Corporation based?

  Bio-Techne Corporation's address is: 614 McKinley Place NE, Minneapolis, MN, United States, 55413

• What is Bio-Techne Corporation's ISIN number?

  Bio-Techne Corporation's international securities identification number is: US09073M1045

• What is Bio-Techne Corporation's CUSIP number?

  Bio-Techne Corporation's Committee on Uniform Securities Identification Procedures number is: 09073M104